A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis

BACKGROUND & AIMS: Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER...

Descripción completa

Detalles Bibliográficos
Autores principales: Henn, Matthew R., O’Brien, Edward J., Diao, Liyang, Feagan, Brian G., Sandborn, William J., Huttenhower, Curtis, Wortman, Jennifer R., McGovern, Barbara H., Wang-Weigand, Sherry, Lichter, David I., Chafee, Meghan, Ford, Christopher B., Bernardo, Patricia, Zhao, Peng, Simmons, Sheri, Tomlinson, Amelia D., Cook, David N., Pomerantz, Roger J., Misra, Bharat K., Auninš, John G., Trucksis, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the AGA Institute 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402096/
https://www.ncbi.nlm.nih.gov/pubmed/32763240
http://dx.doi.org/10.1053/j.gastro.2020.07.048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402096/
https://www.ncbi.nlm.nih.gov/pubmed/32763240
http://dx.doi.org/10.1053/j.gastro.2020.07.048

Ejemplares similares